Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eli Lilly to unveil over 50 oncology studies

Eli Lilly to unveil over 50 oncology studies

6th May 2008

Eli Lilly has announced that it is to unveil over 50 studies at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO).

The conference will be held in Chicago, Illinois from May 30th to June 3rd 2008 and Lilly will present its latest research findings from Alimta (pemetrexed) Gemzar (gemcitabine HCl) and enzastaurin.

It adds that the bulk of the studies to be presented by the firm at the conference are those that support its leadership in thoracic cancer research.

The firm highlighted the pivotal phase III study showing a vital correlation between lung cancer histology, treatment choice and patient outcome, with this study to be featured in the society’s live online presscast.

Richard Gaynor, vice-president of cancer research and global oncology platform leader at Eli Lilly, said: “Improved patient outcomes via tailored therapy continues to be our focus and this year’s ASCO is no exception.”

He added that the meeting will underline the firm’s dedication to answering the currently unmet needs of cancer care, including thoracic and breast cancer.

Last month, Eli Lilly announced that Alimta received approval in Europe for histologically-based use in the first-line treatment of non-small cell lung cancer.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.